v3.26.1
Segment Reporting
 3 Months Ended
Apr. 30, 2026
Segment Reporting [Abstract]  
SEGMENT REPORTING
9 SEGMENT REPORTING

 

We organize and manage our business by the following two segments which meet the definition of reportable segments under ASC280-10, Segment Reporting: Sales of Goods and Services. These segments are based on the customer type of products or services provided and are the same as our business units. Separate financial information is available and regularly reviewed by our chief officer- decision maker, who is our chief executive officer, in making resource allocation decisions for our segments. Our chief officer decision maker evaluates segment performance to the GAAP measure of gross profit.

 

    Three Months Ending  
    April 30,  
    2026     2025  
Net Sales            
Pocono Pharmaceuticals   $ 433,399     $ 667,432  
4P Therapeutics     -       -  
Total     433,399       667,432  
Gross Profit                
Pocono Pharmaceuticals     196,801       251,981  
4P Therapeutics     -       -  
Total     196,801       251,981  
                 
Operating Expense                
Selling, general and administrative - Pocono Pharmaceuticals     156,788       151,528  
Selling, general and administrative - 4P Therapeutics     6,483       19,999  
Selling, general and administrative - Corporate     1,049,734       810,525  
Goodwill and intangibles impairment     -       -  
Research and development - 4P Therapeutics     238,229       683,426  
Total     1,451,234       1,665,478  
                 
Depreciation and Amortization                
Pocono Pharmaceuticals   $ 24,910     $ 42,813  
Corporate     -       -  
4P Therapeutics     9,267       9,267  
Total   $ 34,177     $ 57,480  

 

The following table presents information about net sales and property and equipment, net of accumulated depreciation, in the United States and elsewhere.

 

    Three Months Ending  
    April 30,  
    2026     2025  
Net Sales            
United States   $ 433,399     $ 667,432  
Outside the United States     -       -  
Total   $ 433,399     $ 667,432  

 

Property and equipment, not of accumulated depreciation    April 30,
2026		      January 31,
2026		  
United States   $ 548,244     $ 567,255  
Outside of the United States     -       -  
Total   $ 548,244     $ 567,255  
                 
Assets                
Corporate   $ 3,818,051     $ 4,437,703  
Pocono Pharmaceuticals     1,825,258       1,820,731  
4P Therapeutics     1,248,993       1,294,501  
Total   $ 6,892,302     $ 7,547,935